1st Quarter - Report

SOCIETY FOR NEUROSCIENCE for SOCIETY FOR NEUROSCIENCE

Firm
Client
Income
—
Expenses
$33,687
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

for both FY22 and FY 23 - advocated for continued predictable funds for NIH, NSF, BRAIN Initiative and VA medical and prosthetic research programs and asked Congress not to rely on continuing resolution; advocated for the RISE Act - in ensure funding to restart and reopen biomedical research labs that were impacted but the COVID-19 pandemic shutdowns. Additionally, provided input to congressional offices on the policy development process of ARPA-H.

LobbyistCovered position, as disclosed
KATHRYN GRADY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Animals ANI

for both FY22 and FY23 - advocated for the ethical and responsible use of animals in biomedical research. Specifically, promoting report language for the FY22 LHHS bill to include the importance of animal research, primarily non-human primates (NHPs), used in the COVID-19 vaccine and other discoveries; additionally promoting report language for the FY23 LHHS bill to include the use of NHPs in long haul COVID-19 neuroscience research.

LobbyistCovered position, as disclosed
KATHRYN GRADY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.